Bio-Path Holdings (BPTH) Expands Global Patent Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street wavers as Federal Reserve holds key rate steady, pending more data
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- Oracle sets $225 billion revenue target for FY30 at investor day
- S&P Global explores potential separation of Capital IQ business
- SpaceX stock drops amid spaceport lawsuit, debt concerns
- Rivian shares slip ahead of Thursday earnings release
- Moderna stock rises on latest cancer vaccine data publication
Bio-Path Holdings Expands Global Patent Portfolio
February 13, 2025 4:01 PM ESTHOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced the receipt of newly issued patents in the United States and New Zealand, and updated investors on the extent of its global intellectual property portfolio.
Bio-Path received Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent No. 17/339,366 titled, "P-ethoxy nucleic acids for STAT3 inhibition." The New Zealand Intellectual... More



